Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acetylsalicylic Acid 81 mg Clear all
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 29, 2026, 9:21 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

NCT04301518
View directory record Official record
Conditions
Preterm Labor, Preterm Birth
Interventions
Multimodal intervention strategy
Other
Lead sponsor
Sera Prognostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
18
States / cities
San Diego, California • New Haven, Connecticut • Newark, Delaware + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 29, 2026, 9:21 AM EDT
Completed No phase listed Observational Results available

Aspirin Responsiveness in Women With Coronary Artery Disease

NCT01406990
View directory record Official record
Conditions
CAD
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genotypic and Phenotypic Correlates of Resistance to Aspirin

NCT01361620
View directory record Official record
Conditions
Platelet Dysfunction Due to Aspirin
Interventions
aspirin
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 29, 2026, 9:21 AM EDT
Terminated Not applicable Interventional Results available

Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

NCT02696226
View directory record Official record
Conditions
Aortic Valve Disorder
Interventions
SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel, TAVR Aspirin and clopidogrel
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Phase 2 Interventional

Fish Oil and Aspirin With Type 2 Diabetes

NCT01181882
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fish Oil and Aspirin
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Terminated Phase 2 Interventional Results available

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

NCT04402385
View directory record Official record
Conditions
Pre-Eclampsia, Stage 1 Hypertension, Elevated Blood Pressure
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 29, 2026, 9:21 AM EDT
Terminated Phase 4 Interventional Results available

The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia

NCT03735433
View directory record Official record
Conditions
Preeclampsia
Interventions
162mg aspirin dose
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 29, 2026, 9:21 AM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Active, not recruiting Early Phase 1 Interventional

Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

NCT03771651
View directory record Official record
Conditions
Fallopian Tube Cancer, Fallopian Tube Infection
Interventions
Aspirin 81 mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects

NCT00898222
View directory record Official record
Conditions
Healthy
Interventions
aspirin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 29, 2026, 9:21 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial

NCT07337655
View directory record Official record
Conditions
Pre-term Birth
Interventions
Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg, Standard of Care
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chlorthalidone and HCTZ Impacts on Platelet Activation

NCT02100462
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Phase 4 Interventional

Aspirin and Preeclampsia

NCT04479072
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Phase 4 Interventional

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

NCT06468202
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Aspirin 81 mg, Aspirin 162 mg
Drug
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
10,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Phase 4 Interventional

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

NCT02810704
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thrombosis
Interventions
Enteric Coated Aspirin, Warfarin, Rivaroxaban
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
18,883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

NCT06933056
View directory record Official record
Conditions
Platelet Function and Reactivity Tests
Interventions
Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 29, 2026, 9:21 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 29, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

PREVENTion of Clot in Orthopaedic Trauma

NCT02984384
View directory record Official record
Conditions
Blood Clot, Trauma
Interventions
Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
12,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Miami, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 29, 2026, 9:21 AM EDT